Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

Launched by DALLAS VA MEDICAL CENTER · Jul 10, 2019

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called itraconazole on patients with esophageal cancer, which includes types like esophagus adenocarcinoma and gastroesophageal junction cancer. The trial aims to find out if adding itraconazole to the usual treatment of chemotherapy and radiation therapy can help improve treatment outcomes for patients with localized esophageal cancer. Esophageal cancer is challenging to treat, and researchers hope that itraconazole, which is usually used as an antifungal medication, might also help fight this type of cancer by affecting certain pathways that help tumors grow.

To participate in this trial, patients need to have localized (or locoregional) esophageal or gastroesophageal junction cancer. Eligible patients are generally between the ages of 65 and 74 and should be able to provide consent to join the study. However, those with specific health issues, such as serious heart problems or certain liver conditions, or who are pregnant, cannot participate. If you join the trial, you'll receive the standard treatment plus itraconazole, and the researchers will closely monitor your health to see how well the treatment works. This trial is currently recruiting participants, and it could be an important step in finding better treatments for esophageal cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with localized (locoregional) esophageal cancer
• • Patients diagnosed with localized (locoregional) gastroesophageal junction cancer
• Exclusion Criteria:
• • Patients unwilling or unable to provide informed consent
• • Patients with QTc\>450ms
• • Patients with a history of symptomatic congestive heart failure
• • Patients with LFT's\>3xULN
• • Patients who are pregnant
• • Patients with a known allergy to itraconazole